PDF herunterladen
Pharmacopsychiatry 2021; 54(02): 75-80
DOI: 10.1055/a-1257-0813
Original Paper

Association between Adherence with an Atypical Antipsychotic and with Other Psychiatric Drugs in Patients with Bipolar Disorder

Michael Bauer 
1   Department of Psychiatry and Psychotherapy, University Hospital Carl Gustav Carus Medical Faculty, Technische Universität Dresden, Dresden, Germany
,
Tasha Glenn
2   ChronoRecord Association, Fullerton, CA, USA
,
Martin Alda
3   Department of Psychiatry, Dalhousie University, Halifax, Nova Scotia, Canada
,
Paul Grof
4   Mood Disorders Center of Ottawa, University of Toronto, Toronto, Canada
,
Scott Monteith
5   Michigan State University College of Human Medicine, Traverse City Campus, Traverse City, MI, USA
,
Natalie Rasgon
6   Department of Psychiatry and Behavioral Sciences, Stanford School of Medicine, Palo Alto, CA, USA
,
Emanuel Severus
1   Department of Psychiatry and Psychotherapy, University Hospital Carl Gustav Carus Medical Faculty, Technische Universität Dresden, Dresden, Germany
,
Peter C. Whybrow
7   Department of Psychiatry and Biobehavioral Sciences, Semel Institute for Neuroscience and Human Behavior, University of California Los Angeles (UCLA), Los Angeles, CA, USA
› Institutsangaben
› Weitere Informationen
Auch verfügbar auf
    Lizenzen und Reprints

Abstract

Background Using U.S. pharmacy and medical claims, medication adherence patterns of patients with serious mental illness suggest that adherence to atypical antipsychotics may be related to adherence to other prescription drugs. This study investigated whether adherence to an atypical antipsychotic was related to adherence to other prescribed psychiatric drugs using self-reported data from patients with bipolar disorder.

Methods Daily self-reported medication data were available from 123 patients with a diagnosis of bipolar disorder receiving treatment as usual who took at least 1 atypical antipsychotic over a 12-week period. Patients took a mean of 4.0±1.7 psychiatric drugs including the antipsychotic. The adherence rate for the atypical antipsychotic was compared to that for other psychiatric drugs to determine if the adherence rate for the atypical antipsychotic differed from that of the other psychiatric drug by at least ±10%.

Results Of the 123 patients, 58 (47.2%) had an adherence rate for the atypical antipsychotic that differed from the adherence rate for at least 1 other psychiatric drug by at least±10%, and 65 (52.8%) patients had no difference in adherence rates. The patients with a difference took a larger total number of psychiatric drugs (p<0.001), had a larger daily pill burden (p=0.020) and a lower adherence rate with the atypical antipsychotic (p=0.007), and were more likely to take an antianxiety drug (p<0.001).

Conclusion Adherence with an atypical antipsychotic was not useful for estimating adherence to other psychiatric drugs in about half of the patients with bipolar disorder.

Key words

Bipolar disorder - adherence - atypical antipsychotics


Publikationsverlauf

Eingereicht: 16. Juli 2020
Eingereicht: 31. August 2020

Angenommen: 31. August 2020

Artikel online veröffentlicht:
17. November 2020

© 2020. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 Baldessarini RJ, Vázquez GH, Tondo L. Bipolar depression: A major unsolved challenge. Int J Bipolar Disord 2020; 8: 1
    CrossrefPubMedGoogle Scholar
  • 2 Bohlken J, Bauer M, Kostev K. Drug treatment for patients with bipolar disorders in psychiatric practices in Germany in 2009 and 2018. Psychiatry Res 2020; 289: 112965 10.1016/j.psychres.2020.112965 [published online ahead of print, 2020 May 1]
    CrossrefPubMedGoogle Scholar
  • 3 Hayes J, Prah P, Nazareth I. et al. Prescribing trends in bipolar disorder: Cohort study in the United Kingdom THIN primary care database 1995–2009. PLoS One 2011; 6: e28725
    CrossrefPubMedGoogle Scholar
  • 4 Kessing LV, Vradi E, Andersen PK. Nationwide and population-based prescription patterns in bipolar disorder. Bipolar Disord 2016; 18: 174-182
    CrossrefPubMedGoogle Scholar
  • 5 Lin Y, Mojtabai R, Goes FS, et al. Trends in prescriptions of lithium and other medications for patients with bipolar disorder in office-based practices in the United States: 1996-2015. medRxiv. 2020 Jan 1
    PubMed
  • 6 Rhee TG, Olfson M, Nierenberg AA. et al. 20-year trends in the pharmacologic treatment of bipolar disorder by psychiatrists in outpatient care settings. Am J Psychiatry 2020; 177: 706-715
    CrossrefPubMedGoogle Scholar
  • 7 Bauer M, Glenn T, Alda M. et al. Drug treatment patterns in bipolar disorder: Analysis of long-term self-reported data. Int J Bipolar Disord 2013; 1: 5
    CrossrefPubMedGoogle Scholar
  • 8 Golden JC, Goethe JW, Woolley SB. Complex psychotropic polypharmacy in bipolar disorder across varying mood polarities: A prospective cohort study of 2712 inpatients. J Affect Disord 2017; 221: 6-10
    CrossrefPubMedGoogle Scholar
  • 9 Haeberle A, Greil W, Russmann S. et al. Mono- and combination drug therapies in hospitalized patients with bipolar depression. Data from the European Drug Surveillance Program AMSP. BMC Psychiatry 2012; 12: 153
    CrossrefPubMedGoogle Scholar
  • 10 Gitlin MJ. Lithium: An American perspective. Pharmacopsychiatry 2018; 5: 222-223
    PubMedGoogle Scholar
  • 11 Malhi GS. Lithium: A global perspective. Pharmacopsychiatry 2018; 51: 220-221
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 12 Severus E, Bauer M, Geddes J. Efficacy and effectiveness of lithium in the long-term treatment of bipolar disorders: An update 2018. Pharmacopsychiatry 2018; 51: 173-176
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 13 Tondo L, Alda M, Bauer M. et al. Clinical use of lithium salts: Guide for users and prescribers. Int J Bipolar Disord 2019; 7: 16
    CrossrefPubMedGoogle Scholar
  • 14 Bauer M, Glenn T, Alda M. et al. Trajectories of adherence to mood stabilizers in patients with bipolar disorder. Int J Bipolar Disord 2019; 7: 19
    CrossrefPubMedGoogle Scholar
  • 15 Jawad I, Watson S, Haddad PM. et al. Medication nonadherence in bipolar disorder: A narrative review. Ther Adv Psychopharmacol 2018; 8: 349-363
    CrossrefPubMedGoogle Scholar
  • 16 Pompili M, Serafini G, Del Casale A. et al. Improving adherence in mood disorders: The struggle against relapse, recurrence and suicide risk. Expert Rev Neurother 2009; 9: 985-1004
    CrossrefPubMedGoogle Scholar
  • 17 Shafrin J, Silverstein AR, MacEwan JP. et al. Using information on patient adherence to antipsychotic medication to understand their adherence to other medications. P T 2019; 44: 350-357
    PubMedGoogle Scholar
  • 18 MacEwan JP, Silverstein AR, Shafrin J. et al. Medication adherence patterns among patients with multiple serious mental and physical illnesses. Adv Ther 2018; 35: 671-685
    CrossrefPubMedGoogle Scholar
  • 19 Sajatovic M, Velligan DI, Weiden PJ. et al. Measurement of psychiatric treatment adherence. J Psychosom Res 2010; 69: 591-599
    CrossrefPubMedGoogle Scholar
  • 20 Bauer M, Grof P, Gyulai L. et al. Using technology to improve longitudinal studies: self-reporting with ChronoRecord in bipolar disorder. Bipolar Disord 2004; 6: 67-74
    CrossrefPubMedGoogle Scholar
  • 21 Bauer M, Wilson T, Neuhaus K. et al. Self-reporting software for bipolar disorder: validation of ChronoRecord by patients with mania. Psychiatry Res 2008; 159: 359-366
    CrossrefPubMedGoogle Scholar
  • 22 Coleman CI, Limone B, Sobieraj DM. et al. Dosing frequency and medication adherence in chronic disease. J Manag Care Pharm 2012; 18: 527-539
    CrossrefPubMedGoogle Scholar
  • 23 Ingersoll KS, Cohen J. The impact of medication regimen factors on adherence to chronic treatment: a review of literature. J Behav Med 2008; 31: 213-224
    CrossrefPubMedGoogle Scholar
  • 24 Pantuzza LL, Ceccato MDGB, Silveira MR. et al. Association between medication regimen complexity and pharmacotherapy adherence: A systematic review. Eur J Clin Pharmacol 2017; 73: 1475-1489
    CrossrefPubMedGoogle Scholar
  • 25 Bates JA, Whitehead R, Bolge SC. et al. Correlates of medication adherence among patients with bipolar disorder: results of the bipolar evaluation of satisfaction and tolerability (BEST) study: A nationwide cross-sectional survey. Prim Care Companion J Clin Psychiatry 2010; 12 PCC.09m00883
    PubMedGoogle Scholar
  • 26 Fung VC, Overhage LN, Sylvia LG. et al. Complex polypharmacy in bipolar disorder: Side effect burden, adherence, and response predictors. J Affect Disord 2019; 257: 17-22
    CrossrefPubMedGoogle Scholar
  • 27 Perlis RH, Ostacher MJ, Miklowitz DJ. et al. Clinical features associated with poor pharmacologic adherence in bipolar disorder: Results from the STEP-BD study. J Clin Psychiatry 2010; 71: 296-303
    CrossrefPubMedGoogle Scholar
  • 28 Levin JB, Krivenko A, Bukach A. et al. A reexamination of nonpsychiatric medication adherence in individuals with bipolar disorder and medical comorbidities. J Nerv Ment Dis 2017; 205: 182-187
    CrossrefPubMedGoogle Scholar
  • 29 Bauer R, Glenn T, Alda M. et al. Antidepressant dosage taken by patients with bipolar disorder: Factors associated with irregularity. Int J Bipolar Disord 2013; 1: 26
    CrossrefPubMedGoogle Scholar
  • 30 Pilhatsch M, Glenn T, Rasgon N. et al. Regularity of self-reported daily dosage of mood stabilizers and antipsychotics in patients with bipolar disorder. Int J Bipolar Disord 2018; 6: 10
    CrossrefPubMedGoogle Scholar
  • 31 Aftab A, Levin J, Aebi M. et al. Associations of comorbid anxiety with medication adherence and psychiatric symptomatology in a population of nonadherent bipolar disorder subjects. J Nerv Ment Dis 2018; 206: 258-262
    CrossrefPubMedGoogle Scholar
  • 32 Arvilommi P, Suominen K, Mantere O. et al. Predictors of adherence to psychopharmacological and psychosocial treatment in bipolar I or II disorders—an 18-month prospective study. J Affect Disord 2014; 155: 110-117
    CrossrefPubMedGoogle Scholar
  • 33 Levin JB, Aebi ME, Tatsuoka C. et al. Adherence to psychotropic and nonpsychotropic medication among patients with bipolar disorder and general medical conditions. Psychiatr Serv 2016; 67: 342-345
    CrossrefPubMedGoogle Scholar
  • 34 Okwemba R, Medvedeva E, Wang A. Medication adherence among patients with comorbid diabetes. Psychiatr Serv 2013; 64: 934-935
    CrossrefPubMedGoogle Scholar
  • 35 Bjerrum L, Søgaard J, Hallas J. et al. Polypharmacy: Correlations with sex, age and drug regimen. A prescription database study. Eur J Clin Pharmacol 1998; 54: 197-202
    CrossrefPubMedGoogle Scholar
  • 36 Preskorn S, Werder S. Detrimental antidepressant drug-drug interactions: Are they clinically relevant?. Neuropsychopharmacology 2006; 31: 1605-1613
    CrossrefPubMedGoogle Scholar
  • 37 Sutherland JJ, Daly TM, Liu X. et al. Co-prescription trends in a large cohort of subjects predict substantial drug-drug interactions. PLoS One 2015; 10: e0118991
    CrossrefPubMedGoogle Scholar
  • 38 Bauer M, Glenn T, Keil M. et al. Brief depressive symptoms in patients with bipolar disorder: Analysis of long-term self-reported data. Aust N Z J Psychiatry 2012; 46: 1068-1078
    CrossrefPubMedGoogle Scholar
  • 39 Levin JB, Krivenko A, Howland M. et al. Medication adherence in patients with bipolar disorder: A comprehensive review. CNS Drugs 2016; 30: 819-835
    CrossrefPubMedGoogle Scholar
  • 40 Steiner JF, Ho PM, Beaty BL. et al. Sociodemographic and clinical characteristics are not clinically useful predictors of refill adherence in patients with hypertension. Circ Cardiovasc Qual Outcomes 2009; 2: 451-457
    CrossrefPubMedGoogle Scholar
  • 41 Lehmann A, Aslani P, Ahmed R. et al. Assessing medication adherence: Options to consider. Int J Clin Pharm 2014; 36: 55-69
    CrossrefPubMedGoogle Scholar
  • 42 Garber MC, Nau DP, Erickson SR. et al. The concordance of self-report with other measures of medication adherence: A summary of the literature. Med Care 2004; 42: 649-652
    CrossrefPubMedGoogle Scholar
  • 43 Monnette A, Zhang Y, Shao H. et al. Concordance of adherence measurement using self-reported adherence questionnaires and medication monitoring devices: An updated review. Pharmacoeconomics 2018; 36: 17-27
    CrossrefPubMedGoogle Scholar
  • 44 Shi L, Liu J, Koleva Y. et al. Concordance of adherence measurement using self-reported adherence questionnaires and medication monitoring devices. Pharmacoeconomics 2010; 28: 1097-1107
    CrossrefPubMedGoogle Scholar
  • 45 Tonin FS, Wiecek E, Torres-Robles A. et al. An innovative and comprehensive technique to evaluate different measures of medication adherence: The network meta-analysis. Res Social Adm Pharm 2019; 15: 358-365
    CrossrefPubMedGoogle Scholar
  • 46 Sylvia LG, Shelton RC, Kemp DE. et al. Medical burden in bipolar disorder: Findings from the Clinical and Health Outcomes Initiative in Comparative Effectiveness for Bipolar Disorder study (Bipolar CHOICE). Bipolar Disord 2015; 17: 212-223
    CrossrefPubMedGoogle Scholar
  • 47 Sylvia LG, Hay A, Ostacher MJ. et al. Association between therapeutic alliance, care satisfaction, and pharmacological adherence in bipolar disorder. J Clin Psychopharmacol 2013; 33: 343-350
    CrossrefPubMedGoogle Scholar
  • 48 Bjornestad J, Lavik KO, Davidson L. et al. Antipsychotic treatment – a systematic literature review and meta-analysis of qualitative studies. . J Ment Health 2020; 29: 513-523
    CrossrefPubMedGoogle Scholar
  • 49 Rosenblat JD, Simon GE, Sachs GS. et al. Treatment effectiveness and tolerability outcomes that are most important to individuals with bipolar and unipolar depression. J Affect Disord 2019; 243: 116-120
    CrossrefPubMedGoogle Scholar
  • 50 Sajatovic M, Jenkins JH. Is antipsychotic medication stigmatizing for people with mental illness?. Int Rev Psychiatry 2007; 19: 107-112
    CrossrefPubMedGoogle Scholar
  • 51 Strejilevich SA, Camino S, Caravotta P. et al. Subjective response to antipsychotics in bipolar disorders: A review of a neglected area. Eur Psychiatry 2019; 62: 45-49
    CrossrefPubMedGoogle Scholar